To obtain a new compound having high affinity for and an excellent selectivity to a dopamine transporter(DAT), capable of forming a complex labeled with radioactive substance 99mTc, and enabling the formed radioactive complex useful for detecting tropane recognition sites containing neurocytes such as a DAT when used as an imaging agent and for the early stage diagnosis and treatment of degenerative neuropathy.
This new compound is expressed by the formula [wherein R1 is an αor β-COORa (wherein Ra is a 1-5C alkyl or the like); R2 is an α- or β-C6H3XY (wherein X and Y are each Ra, H or the like); a bond between carbons at 2- and 3-positions is a single bond or a double bond; L is (CH2)n (wherein (n) is an integer of 1 to 6) or the like and; Ch is a tridentate or tetradentate ligand capable of forming a neutral complex labeled with technetium(Tc) or rhenium(Re)]. The compound is obtained e.g. by alkylating the chelating ligand with a haloalkylflate and then adding to an adequate nortropane. A radioactive substance for forming a complex is preferably Tc or Re.
MADRAS BERTHA K
BLUNDELL PAUL
MAHMOOD ASHFAQ
JONES ALUN G
FISCHMAN ALAN J
ORGANIX INC
GEN HOSPITAL CORP
WO1997016210A1 | 1997-05-09 |